Literature DB >> 11160750

Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

D H Barouch1, A Craiu, S Santra, M A Egan, J E Schmitz, M J Kuroda, T M Fu, J H Nam, L S Wyatt, M A Lifton, G R Krivulka, C E Nickerson, C I Lord, B Moss, M G Lewis, V M Hirsch, J W Shiver, N L Letvin.   

Abstract

Increasing evidence suggests that the generation of cytotoxic T-lymphocyte (CTL) responses specific for a diversity of viral epitopes will be needed for an effective human immunodeficiency virus type 1 (HIV-1) vaccine. Here, we determine the frequencies of CTL responses specific for the simian immunodeficiency virus Gag p11C and HIV-1 Env p41A epitopes in simian-human immunodeficiency virus (SHIV)-infected and vaccinated rhesus monkeys. The p11C-specific CTL response was high frequency and dominant and the p41A-specific CTL response was low frequency and subdominant in both SHIV-infected monkeys and in monkeys vaccinated with recombinant modified vaccinia virus Ankara vectors expressing these viral antigens. Interestingly, we found that plasmid DNA vaccination led to high-frequency CTL responses specific for both of these epitopes. These data demonstrate that plasmid DNA may be useful in eliciting a broad CTL response against multiple epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160750      PMCID: PMC114830          DOI: 10.1128/JVI.75.5.2462-2467.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype.

Authors:  M F del Guercio; J Sidney; G Hermanson; C Perez; H M Grey; R T Kubo; A Sette
Journal:  J Immunol       Date:  1995-01-15       Impact factor: 5.422

2.  An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.

Authors:  K A Reimann; J T Li; G Voss; C Lekutis; K Tenner-Racz; P Racz; W Lin; D C Montefiori; D E Lee-Parritz; Y Lu; R G Collman; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Humoral and cellular immunities elicited by HIV-1 vaccination.

Authors:  J W Shiver; M E Davies; H C Perry; D C Freed; M A Liu
Journal:  J Pharm Sci       Date:  1996-12       Impact factor: 3.534

4.  Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

Authors:  L S Wyatt; S S Whitehead; K A Venanzi; B R Murphy; B Moss
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

5.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

7.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

8.  A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.

Authors:  Y Yasutomi; S Koenig; R M Woods; J Madsen; N M Wassef; C R Alving; H J Klein; T E Nolan; L J Boots; J A Kessler
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 envelope glycoprotein-specific cytotoxic T lymphocytes in simian-human immunodeficiency virus-infected rhesus monkeys.

Authors:  G Voss; J Li; K Manson; M Wyand; J Sodroski; N L Letvin
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

10.  T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus.

Authors:  Z W Chen; Z C Kou; C Lekutis; L Shen; D Zhou; M Halloran; J Li; J Sodroski; D Lee-Parritz; N L Letvin
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

View more
  35 in total

1.  Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.

Authors:  Todd M Allen; Lorenzo Mortara; Bianca R Mothé; Max Liebl; Peicheng Jing; Briana Calore; Marian Piekarczyk; Richard Ruddersdorf; David H O'Connor; X Wang; Chenxi Wang; David B Allison; John D Altman; Alessandro Sette; Ronald C Desrosiers; Gerd Sutter; David I Watkins
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

5.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

6.  Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.

Authors:  Miranda Z Smith; C Jane Dale; Robert De Rose; Ivan Stratov; Caroline S Fernandez; Andrew G Brooks; Jason Weinfurter; Kendall Krebs; Cara Riek; David I Watkins; David H O'connor; Stephen J Kent
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

8.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.

Authors:  Ying Xu; Enzhuo Yang; Jianguang Wang; Rui Li; Guanghua Li; Guoyuan Liu; Na Song; Qi Huang; Cong Kong; Honghai Wang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

10.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.